BioCryst: Difference between revisions

From Bhamwiki
Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical research company founded in [[1986]] in [[Birmingham]] as a spin-off of [[UAB]] research conducted by [[Charles Bugg]] and [[John Montgomery]]. [[William Spencer III]], who had been involved in the launch of [[Molecular Engineering Associates]], helped the company raise start-up investments.
'''BioCryst Pharmaceuticals Inc.''' (NASDAQ:BDRX) is a pharmaceutical research company founded in [[1986]] in [[Birmingham]] as a spin-off of [[UAB]] research conducted by [[Charles Bugg]] and [[John Montgomery]]. [[William Spencer III]], who had been involved in the launch of [[Molecular Engineering Associates]], helped the company raise start-up investments.


BioCryst went public in [[1994]] and moved its headquarters to Raleigh, North Carolina in [[2010]]. It maintains a 35,000 square-foot "Discovery Research Center and Laboratory Center of Excellence" with approximately 60 employees in Birmingham. The center is headed by chief discovery officer [[Yarlagadda Babu]].
BioCryst went public in [[1994]] and moved its headquarters to Durham, North Carolina in [[2010]]. It maintains a 35,000 square-foot "Discovery Research Center and Laboratory Center of Excellence" (or "Discovery Center of Excellence") with approximately 60 employees at [[2100 Riverchase Center]] in [[Riverchase Corporate Park]]. The center is headed by chief discovery officer [[Yarlagadda Babu]].


Formerly headquartered at 2190 [[Parkway Lake Drive]], BioCryst develops and manufactures various types of prescription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.
Formerly headquartered at 2190 [[Parkway Lake Drive]], BioCryst develops and manufactures various types of prescription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.


BioCryst merged with Idera Pharmaceuticals of Exton, Pennsylvania in [[2018]].
BioCryst planned to merge with Idera Pharmaceuticals of Exton, Pennsylvania in [[2018]], but the move was blocked by shareholders in July.
 
In April [[2023]] BioCryst negotiated a $450 million 5-year financing agreement with Pharmakon Advisors of New York City. The deal provided funds to repay $241.8 million in existing debts to Athyrium Capital Management.
 
Later that year, BioCryst made plans to expand its research and manufacturing facility to 49,054 square feet, occupying the entire 2100 Riverchase Center building. The [[City of Hoover]] provided $1,828,470 in tax abatements over 10 years to support the expansion.


==Chief executives==
==Chief executives==
* [[Charles Bugg]], 1986-2007
* [[Charles Bugg]], 1986-2007
* [[Jon Stonehouse]], 2007-2018
* [[Jon Stonehouse]], 2007–
* Vincent Milano, 2018-


==Products==
==Products==
BioCryst has developed several drug treatments:
BioCryst has developed several drug treatments:
* Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
* Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
* Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
* Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
Line 22: Line 26:
* Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
* Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
* BCX-4208 Oral, for treatment of Hepatitis C
* BCX-4208 Oral, for treatment of Hepatitis C
* Orladeyo, for prevention of recurrent hereditary angioedema attacks (approved by FDA and European Medicines Agency)
* BCX-7353 ('Orladeyo"), for prevention of recurrent hereditary angioedema attacks (approved by FDA and European Medicines Agency)


==References==
==References==
Line 31: Line 35:
* Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." {{BBJ}}
* Piper, Ben (October 13, 2010) "BioCryst Pharmaceuticals Inc. moving HQ to North Carolina." {{BBJ}}
* Patchen, Tyler (January 23, 2018) "BioCryst Pharmaceuticals to merge with Pennsylvania pharmaceutical company." {{BBJ}}
* Patchen, Tyler (January 23, 2018) "BioCryst Pharmaceuticals to merge with Pennsylvania pharmaceutical company." {{BBJ}}
* Henderson, Jennifer (July 23, 2018) "No deal: BioCryst shareholders thwart merger with Idera." {{BBJ}}
* Patchen, Tyler (May 14, 2021) "BioCryst Pharmaceuticals expands in Birmingham." {{BBJ}}
* Patchen, Tyler (May 14, 2021) "BioCryst Pharmaceuticals expands in Birmingham." {{BBJ}}
* Ezzone, Zac & Laurel Thrailkill (April 20, 2023) "Pharma with Bham presence takes $300M loan to pay down debt." {{BBJ}}
* Thrailkill, Laurel (November 7, 2023) "Major biotech company to get $1.8M in tax incentives from Hoover." {{BBJ}}


==External links==
==External links==
Line 40: Line 47:
[[Category:Pharmaceuticals]]
[[Category:Pharmaceuticals]]
[[Category:Parkway Lake Drive]]
[[Category:Parkway Lake Drive]]
[[Category:2100 Riverchase Center]]

Revision as of 17:34, 7 November 2023

BioCryst logo.png

BioCryst Pharmaceuticals Inc. (NASDAQ:BDRX) is a pharmaceutical research company founded in 1986 in Birmingham as a spin-off of UAB research conducted by Charles Bugg and John Montgomery. William Spencer III, who had been involved in the launch of Molecular Engineering Associates, helped the company raise start-up investments.

BioCryst went public in 1994 and moved its headquarters to Durham, North Carolina in 2010. It maintains a 35,000 square-foot "Discovery Research Center and Laboratory Center of Excellence" (or "Discovery Center of Excellence") with approximately 60 employees at 2100 Riverchase Center in Riverchase Corporate Park. The center is headed by chief discovery officer Yarlagadda Babu.

Formerly headquartered at 2190 Parkway Lake Drive, BioCryst develops and manufactures various types of prescription drugs. Its two most well-known products include the influenza drug Peramivir, a treatment of T-cell mediated disorders called BCX-1777 and another treatment for T-cell mediated autoimmune diseases called BCX-4208.

BioCryst planned to merge with Idera Pharmaceuticals of Exton, Pennsylvania in 2018, but the move was blocked by shareholders in July.

In April 2023 BioCryst negotiated a $450 million 5-year financing agreement with Pharmakon Advisors of New York City. The deal provided funds to repay $241.8 million in existing debts to Athyrium Capital Management.

Later that year, BioCryst made plans to expand its research and manufacturing facility to 49,054 square feet, occupying the entire 2100 Riverchase Center building. The City of Hoover provided $1,828,470 in tax abatements over 10 years to support the expansion.

Chief executives

Products

BioCryst has developed several drug treatments:

  • Fodosine IV, for treatment of T-cell leukemia (Phase II/IIb)
  • Fodosine Oral, for treatment of cutaneous T-cell lymphoma (Phase I/II)
  • Fodosine Oral, for treatment of chronic lymphocytic leukemia (Phase I/II)
  • Fodosine IV, for treatment of B-cell acute lymphoblastic leukemia (Phase I/II)
  • BCX-4208 Oral, for treatment of autoimmune diseases/transplantation (Phase I)
  • Peramivir IV/IM, for treatment of seasonal/life-threatening influenza (Phase I)
  • BCX-4208 Oral, for treatment of Hepatitis C
  • BCX-7353 ('Orladeyo"), for prevention of recurrent hereditary angioedema attacks (approved by FDA and European Medicines Agency)

References

External links

Retrieved from "http://bhamwiki.com/w/index.php?title=BioCryst&oldid=208378"